Advertisement
Canada markets close in 3 hours 34 minutes

  • S&P/TSX

    21,985.43
    +100.05 (+0.46%)
     

  • S&P 500

    5,103.89
    +55.47 (+1.10%)
     

  • DOW

    38,252.91
    +167.11 (+0.44%)
     

  • CAD/USD

    0.7312
    -0.0012 (-0.16%)
     

  • CRUDE OIL

    84.04
    +0.47 (+0.56%)
     

  • Bitcoin CAD

    87,059.04
    -634.71 (-0.72%)
     

  • CMC Crypto 200

    1,320.19
    -76.34 (-5.23%)
     

  • GOLD FUTURES

    2,350.00
    +7.50 (+0.32%)
     

  • RUSSELL 2000

    1,998.85
    +17.73 (+0.89%)
     

  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     

  • NASDAQ

    15,934.94
    +323.18 (+2.07%)
     

  • VOLATILITY

    15.29
    -0.08 (-0.52%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Canntab Announces Director Resignation

Newsfile Corp.
Updated

Toronto, Ontario--(Newsfile Corp. - June 14, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") announces that Sheldon Inwentash has resigned from the Company's Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, "I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours."

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the "Medical" into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
info@canntab.ca

ADVERTISEMENT

Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.